Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on May 6, 2025
SRx Health Solutions to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET
GlobeNewswire
·
May 6, 2025
TAMPA, Fla., May 06, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”), a leading global health and wellness company, today announced it will host a conference call and webcast on Thursday, May 15, 2025, at 4:30 p.m. …
Digital Utilities Ventures CEO Mark Gaalswyk Meets with QFFD in Qatar
GlobeNewswire
·
May 6, 2025
Strategic Partnership with QFFD to Transform Agriculture and Water Sustainability in Africa: Easy Environmental Solutions, Inc. (OTC: DUTV) is actively engaging with the Qatar Fund for Development (QFFD) and multiple African governments to launch scalable …
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
GlobeNewswire
·
May 6, 2025
VANCOUVER, Washington, May 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that …
Viemed Executes Diversification Strategy With $26 Million Acquisition of Home Equipment Provider in Illinois
GlobeNewswire
·
May 6, 2025
LAFAYETTE, La., May 06, 2025 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ: VMD), an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, announced that it has …
Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025
GlobeNewswire
·
May 6, 2025
SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of …
Alpha Tau to Participate in May Investor Conferences
GlobeNewswire
·
May 6, 2025
JERUSALEM, May 06, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will presentation in …
Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases
GlobeNewswire
·
May 6, 2025
Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response Company advancing Phase 1a/b study of PALI-2108 and has …
Intelligent Bio Solutions Drives Global Growth Through Multilingual Digital Expansion
GlobeNewswire
·
May 6, 2025
Arabic, Italian, and Spanish-language websites unlock commercial access to regions representing over 1.4 billion people Multilingual rollout aligns with product readiness and accelerates international sales pipeline development NEW YORK, May 06, 2025 ( …
Sofwave Medical Reports First Quarter Fiscal 2025 Financial Results and Business Highlights
GlobeNewswire
·
May 6, 2025
— First quarter revenue of $16.7M, +26% year-over-year growth; IFRS gross margin of 76.3% — First quarter pulse recurring revenue of $7.0M, +49% year-over-year growth — IFRS and non-IFRS operating loss of -$1M and -$0.2M, respectively SAN CLEMENTE, Calif., …
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
GlobeNewswire
·
May 6, 2025
Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development …
UMeWorld Releases Clinical Results: DAG Oil Shows Significant Reductions in Uric Acid, Cholesterol, Triglycerides, and Weight
GlobeNewswire
·
May 6, 2025
MIAMI, May 06, 2025 (GLOBE NEWSWIRE) -- UMeWorld Limited (OTC: UMEWF) today announced the results of a clinical study demonstrating the metabolic benefits of diacylglycerol (DAG) oil, the active ingredient in its functional cooking oil brand, DAGola. The …
Nova Leap Health Corp. announces Closing of Home Care Acquisition in Nova Scotia
GlobeNewswire
·
May 6, 2025
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, May 06, 2025 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) ("Nova Leap" or “the Company”), a growing home health care organization, is …
Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US
GlobeNewswire
·
May 6, 2025
WARRINGTON, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies …
FOXO TECHNOLOGIES INC.’S BEHAVIORAL HEALTH SUBSIDIARY REACHES KEY OPERATIONAL MILESTONES
GlobeNewswire
·
May 6, 2025
WEST PALM BEACH, FLORIDA, May 06, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that its behavioral health subsidiary, Myrtle Recovery Centers, Inc., has reached key patient care milestones. …
IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology
GlobeNewswire
·
May 6, 2025
Data from OVATION 2 trial will also be reviewed in an oral presentation at ASCO Annual Meeting on June 3, 2025 LAWRENCEVILLE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its …
Candel Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire
·
May 6, 2025
NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, …
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference
GlobeNewswire
·
May 6, 2025
WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …
Boehringer Ingelheim starts Phase II study of its potential first-in-class oral compound as a treatment for Geographic Atropy
GlobeNewswire
·
May 6, 2025
Ingelheim, Germany, May 6, 2025 – Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a potential first-in-class treatment for geographic atrophy (GA).[1 …
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
May 6, 2025
NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and acceptable safety at clinically relevant doses; preclinical …
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
GlobeNewswire
·
May 6, 2025
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David …